Chlorogenic acid sustained-release gel for treatment of glioma and hepatocellular carcinoma

Eur J Pharm Biopharm. 2021 Sep:166:103-110. doi: 10.1016/j.ejpb.2021.05.028. Epub 2021 Jun 14.

Abstract

Chlorogenic acid (CGA) may provide an effective and safe option for tumor treatment. However, its application is limited because of short residence time in vivo and repeated administration required. A phospholipid-based in situ gel containing chlorogenic acid (CGA PG) was prepared via a simple way. The CGA PG exhibited good fluidity, easy injectability, high-drug-loading capacity, and suitable sustained-release behavior whether in vitro or in vivo. Furthermore, CGA PG could suppress tumor growth with no significant side effects. Overall, CGA PG may be a promising sustained drug delivery system with excellent therapeutic effect on glioma and hepatocellular carcinoma.

Keywords: Chlorogenic acid; Glioma; Hepatocellular carcinoma; Phospholipid in situ gel; Sustained drug delivery system.

MeSH terms

  • Animals
  • Brain Neoplasms / drug therapy*
  • Carcinoma, Hepatocellular / drug therapy*
  • Cells, Cultured
  • Chlorogenic Acid / pharmacology*
  • Delayed-Action Preparations / pharmacology
  • Drug Delivery Systems
  • Gels
  • Glioma / drug therapy*
  • Injections / methods
  • Liver Neoplasms / drug therapy*
  • Mice
  • Phospholipids / pharmacology*
  • Rats
  • Treatment Outcome

Substances

  • Delayed-Action Preparations
  • Gels
  • Phospholipids
  • Chlorogenic Acid